Upon authorization by the European Commission (EC), the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...

Pfizer and BioNTech said Friday that the immune responses against omicron BA.4/BA.5 subvariants were "substantially higher" in people who got its new bivalent booster compared with people who received ...

NEW YORK and MAINZ, GERMANY, November 4, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (BNTX) (Nasdaq: BNTX) today announced updated data from a Phase 2/3 clinical trial demonstrating a robust ...

Nov 18 (Reuters) - Pfizer Inc PFE.N and its German partner BioNTech SE BNTX.O said on Friday their Omicron-tailored shot produced higher virus-neutralizing antibodies in older adults against the ...

Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; ...

As the COVID-19 pandemic has swept the globe, more than 5.2 million people have died from the disease worldwide, including over 791,000 Americans, according to real-time data compiled by Johns Hopkins ...

Pfizer and BioNTech have begun a clinical trial for their Omicron-specific Covid-19 vaccine candidate, they announced in a news release on Tuesday. Pfizer and BioNTech have begun a clinical trial for ...

BioNTech is the Marketing Authorization Holder for COMIRNATY ® and its adapted vaccines (COMIRNATY ® Original/Omicron BA.4-5; COMIRNATY ® Omicron XBB.1.5) in the United States, the European Union, the ...

BioNTech is the Marketing Authorization Holder for COMIRNATY ® and its adapted vaccines (COMIRNATY ® Original/Omicron BA.4/5; COMIRNATY ® Omicron XBB.1.5) in the United States, the European Union, the ...